跳至主要内容
临床试验/NCT00382772
NCT00382772已完成3 期

Study to Evaluate Clinical Consistency of the Liquid Formulation of GSK Biologicals' HRV Vaccine and to Evaluate Liquid Formulation Compared to Lyophilised Formulation of the HRV Vaccine Administered as a Two-dose Primary Vaccination.

GlaxoSmithKline13 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2006年11月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
1,200
试验地点
13
主要终点
Demonstrate lot-to-lot consistency of HRV vaccine liquid formulation and non-inferiority of liquid formulation versus the lyophilised formulation of the HRV vaccine.

研究概览

简要总结

The aim of this this study is to evaluate the lot-to-lot consistency of the liquid formulation of GSK Biologicals' HRV vaccine and to evaluate the liquid formulation compared to the lyophilised formulation of GSK Biologicals' HRV vaccine when administered concomitantly with a combination childhood vaccine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double

入排标准

年龄范围
11 Weeks 至 17 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • Healthy infants birth weigh >2000 g, 11 -17 weeks old at Dose 1 with written informed consent.

排除标准

  • Allergic reaction to vaccine components; clinically significant history of chronic GI disease (uncorrected GI congenital malformation) or other serious medical condition per investigator, received vaccines or treatment prohibited by the protocol; immunocompromised.

结局指标

主要结局

Demonstrate lot-to-lot consistency of HRV vaccine liquid formulation and non-inferiority of liquid formulation versus the lyophilised formulation of the HRV vaccine.

次要结局

  • Assess lot-to-lot consistency in terms of reactogenicity and assess safety of HRV vaccines.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验